



**Freedom of Information Request**

**Ref: UHB 19-570**

24 September 2019

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

1. Does your trust treat Hereditary angioedema HAE?  
No.
2. In the last 6 months, how many patients with Hereditary angioedema (HAE) have been treated with,
  - a. Berint
  - b. Cinryze
  - c. Firazyr
  - d. Ruconest
  - e. Takhzyro
  - f. Tranexamic acid
  - g. OtherN/A.
3. Over the past 6 months, how many patients with persistent / chronic\* Immune thrombocytopenia purpura [ITP] have you treated [include all treatments such as steroids, splenectomy, immune globulins, Rituximab and TPOs]?  
43 patients.
4. Over the past 6 months, how many patients with persistent / chronic\* Immune thrombocytopenia purpura [ITP] were new to treatment with the following;
  - Eltrombopag [Revolade]: 2
  - Romiplostim [Nplate]: 7

Please note that we have gone back a year instead of 6 months.

\*Patient has ITP for over 6 months and does not respond to standard active treatments.

5. Over the past 6 months, how many patients have you treated with the following conditions and treatments. If None, please state None.

	Total patients	Eltrombopag [Revolade]	Romiplostim [Nplate]
Immune thrombocytopenia purpura [ITP]	43	2	7
Chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy	Not treated in hepatology.	Not treated in Haematology	Not in Haemophilia Centre
Acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pre-treated and are unsuitable for haematopoietic stem cell transplantation	Drugs not NHS of NICE approved. No patients treated with these via IFR in past 6 months.	0	0
Chemotherapy induced thrombocytopenia (CIT)	Drugs not NHS of NICE approved. No patients treated with these via IFR in past 6 months.	0	0
Myelodysplastic syndromes (MDS)	Drugs not NHS of NICE approved. No patients treated with these via IFR in past 6 months.	0	0

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Trust Secretary  
 University Hospitals Bristol NHS Foundation Trust  
 Trust Headquarters  
 Marlborough Street  
 Bristol  
 BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

### Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

**FOI Team**  
**UH Bristol NHS Foundation Trust**